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Abstract: 
Background: Chronic myeloid leukaemia (CML) is a 
clonal myeloproliferative disorder of transformed 
primitive hematopoietic progenitor cells. Chronic myeloid 
leukaemia is one of the commonest leukemias. Patients of 
CML are usually subjected to risk stratification according 
to various prognostic criteria. The Sokal scoring system is 
popular as a prognostic discriminator for survival in 
patients treated with chemotherapy. Hasford et al 
proposed a new CML scoring system referred to as Euro 
score. 
Objective: Correlation of various prognostic risk 
groups of Hasford scoring system with comparable 
prognostic groups of Sokal scoring system in chronic 
myeloid leukemia. 
Material and Methods: This descriptive study was 
conducted at department of pathology, Pakistan institute 
of medical sciences from March 2003 to October 2006. A 
total of 59 consecutive freshly diagnosed untreated cases of 
CML were subjected to Sokal and Hasford scoring 
systems, and the results were correlated with each other. 
Results: In total of 59 cases of CML age range was from 8 
to 70 years with mean ± SD of 35.39 ± 17.12 years. Six 
(10.1%) patients belonged to pediatric age group i.e. <15 
years. Male: female ratio was 1.3:1.  According to Sokal 
criteria about half of the patients were found in 
intermediate risk group; 44% were in high risk group and 
only 5% in low risk group. Using Hasford scoring system, 
44% of patients were placed in intermediate risk, 30.5% in 
high risk and 15% in low risk groups.  
Conclusion: Hasford score identifies more patients 
still in low risk group as compared to Sokal scoring system 
and prospective studies should be carried out to see 
overall survival and disease free survival of these risk 
groups.  
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Scoring; Hasford scoring; prognostic stratification   
 
Introduction 
Chronic myeloid leukaemia is a clonal myeloproliferative 
disorder of transformed primitive hemopoietic progenitor 
cells, and is characterized by expansion of proliferating 
myeloid cell pool especially in the bone marrow, spleen and 
peripheral blood. CML is the commonest type of chronic 
leukemia in Pakistan, and accounts for about 15 percent of 
leukemias in adults. The median age of patients at 
presentation is 45 to 55 years. From 12-30 % of patients are 
60 years of age or older.1 In more than 90% cases of CML, 
Philadelphia chromosome is observed. This chromosome is 
produced as a result of reciprocal translocation between 
chromosomes 9 and 22. This translocation results in the 
production of a fusion gene, i.e. bcr-abl gene; the latter 
perturbs downstream signalling pathways in hematopoietic 
progenitor cells and produces the clinical phenotype of 
overproduction of mature myeloid cells.2 The majority of 
CML patients have WBCs in excess of 100,000/µl at 
diagnosis. Depressed erythropoiesis proportional to the 
increase in myeloid cells results in anaemia in some 
patients. Platelet counts are elevated in 30% to 50% of cases 
at diagnosis.3  
CML usually runs a biphasic or triphasic course. This 
process includes an initial chronic phase and a terminal 
blastic phase, which is preceded by an accelerated phase in 
60% -80% of patients.4 Many patients, especially if they 
present with delay, may have accelerated or even blast stage 
at the onset. Splenomegaly is documented in 30-70% of 
cases. The liver is enlarged in 10-40% of cases. 5  
Risk stratification of CML patients on the basis of variable 
prognostic factors was first proposed by Tura et al ( 1981) 
who stratified their patients into three groups, depending on 
presence or absence of six variables (splenomegaly, 
hepatomegaly, blast cells, leukocytosis, thrombocytosis and 
a rise in granulated precursor cells ) as follows: 
Low risk group; upto one risk factor present 
Intermediate risk group; upto two or three risk factors 
High risk group; more than three risk factors present 6 
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Carvantes and Rozman (1982) emphasized on 
splenomegaly, erythroid precursors in blood and over 5% 
myeloblasts in the marrow as main prognostic factors, and 
stratified their patients as under: 7 
Low risk group; upto one factor present 
Intermediate risk group; two factors present 
High risk group; three or four risk factors present 
Kantarjian et al (1990) introduced the so called simple 
synthetic prognostic staging system. 8 The Sokal score 
achieved widespread usage as a prognostic discriminator for 
survival in patients treated with chemotherapy (mainly 
busulfan and hydroxyurea).9 This scoring system was based 
on a formula that takes into account the patients age, the 
blast cell count and the spleen size at the time of diagnosis. 
The Hasford CML score also called the Euro score, uses 
age, spleen size (measured from the left costal margin), blast 
cell count, platelet count, and eosinophil count. All variables 
are measured at the time of diagnosis.10 
This study was aimed to correlate various prognostic groups 
of Sokal and Hasford scoring systems in freshly diagnosed 
untreated cases of CML. 
 
Material and Methods 
This cross-sectional study was conducted at the department 
of pathology, Pakistan Institute of Medical Sciences from 
March 2003 to October 2006. A total of 59 consecutive 
freshly diagnosed cases of CML belonging to all age groups, 
both sexes and all the three clinical phases were included. 
Patients of CML who had received cytotoxic treatment 
previously were excluded from the study. A detailed account 
of clinical history and physical examination was entered in a 
performa specially pertaining to age, sex, duration of 
symptoms, history of fever and other constitutional features 
due to anaemia, bleeding, splenomegaly and hepatomegaly. 
In every patient about 5ml EDTA blood sample was 
collected. Complete blood counts were performed on a fully 
automated haematology analyzer (Sysmex KX-21). 
Peripheral blood smears were freshly prepared and stained 
using Wright stain. The slides were examined under a 
microscope and differential count was performed. 
Neutrophil alkaline phosphatase (NAP) scoring was done on 
peripheral blood films to differentiate from leukemoid 
reaction. Bone marrow aspiration was done; multiple smears 
were made and at least two smears were stained by Wright 
stain. The smears were examined and at least five hundred 
cells were counted for myelogram. 
 
Table 1: Stratification of cases of CML into clinical 
phases 
Diagnosis No. of patients % 
CML in chronic phase 
CML in accelerated phase 
CML in blastic phase 
55 
03 
01 
93.2 
5.1 
1.7 
Patients were placed in chronic, accelerated and blastic 
phases according to the known criteria. Cytogenetic and 
molecular studies could not be done due to lack of these 
facilities at PIMS.  
Sokal prognostic scoring was performed on all the cases 
using the following formula: 
Exp.[0.0116(age -4.34)+0.0345(spleen-7.51)-0.188(% of 
blasts-2.1)] According to Sokal score the patients were 
stratified into various prognostic groups as shown below; 
Low risk (good prognosis) group with score <0.8 
Intermediate risk (moderate prognosis)group with score of 
0.8 -1.2 
High risk (poor prognosis) group with score >1.2 
Hasford score was also performed on all cases using the 
formula:  
0.6666 x age [0 when age <50 years;1,otherwise]+0.0420 x 
spleen size[cm below costal margin] + 0.0584 x 
blasts[%]+0.0413 
x Eosinophils [%]+0.2039 
x Basophils[0 when basophils < 3%; 1. otherwise] + 1.0956 
x Platelet count[0 when platelets < 1,500 x 109/L; 1, 
Otherwise]x1,000. 
Based on the score obtained, the patients were stratified into 
various groups as follows: 
Low risk group <780  
Intermediate risk group >780 and <1480 
High risk group >1480  
The results were statistically analyzed using the statistical 
programme SPSS version 13. 
Correlation of various prognostic groups of Hasford and 
Sokal scoring system was also done.  
 
Table 2: Prognostic stratification of CML cases 
Prognostic groups Sokal score Hasford score 
Low risk 
Intermediate risk 
High risk 
03 (5.1%) 
30 (50.8%) 
26 (44.1%) 
15 (25.4%) 
26 (44.1%) 
18 (30.5%) 
 
Results 
Age distribution: In a total of 59 cases of CML included in 
this study, the age of patients ranged from 8 to 70 years with 
mean ± SD of 35.39 ± 17.12 years. The median age was 35 
years. Among these 34 were male and 25 female. The male 
to female ratio was 1.3:1. Feeling of weakness and lassitude 
were invariably present. History of low grade fever was 
given by 85% of cases. In 76% of cases, pallor was a 
presenting manifestation. Hepatomegaly was present in 37 
(63%) of cases. Spleen was enlarged in 95% cases. The 
range of blasts in the bone marrow was 1-22% with mean of 
3.6% + 3.75 SD.  
As shown in table 1, majority (93.2 %) of patients were in 
chronic phase; 6.8% were in accelerated phase, and 1.7% 
presented with blast crisis.  
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According to Hasford score 26 (44%) of patients were 
placed in intermediate risk group; 18 (30.5 %) were in high 
risk group and 15 (25.5%) patients were grouped under low 
risk group. Whereas according to Sokal Score, majority of 
the patients were in intermediate (50.8%) and poor (44.1%) 
prognosis groups; only 5.1% cases were observed to be in 
good prognosis group. (table 2) 
 
Discussion 
Typically CML if diagnosed in chronic phase can usually be 
controlled for some years; however, the disease invariably 
progresses eventually to more advanced (accelerated phase 
or blast transformation) which (particularly the blastic 
phase) are resistant to therapy and lead to death within 6–8 
months.11 The management of CML has progressively 
revolutionized during the last two decades. The treatment 
modalities switched on from busulphan and hydroxyurea to 
bone marrow transplantation and interferon therapy, and 
now molecular lesion targeted therapy using imatinib 
mesylate (Glevac) has incredibly improved the outlook of 
CML patients. Considering the importance of prognostic 
factors and their impact on various treatment modalities, 
many CML study groups have worked in this area. Many 
attempts have been made in the last 20 years to define 
clinical factors assessed at the time of diagnosis that may 
predict survival for individual patients with CML.12 For 
example, Sokal et al identified factors that allow them to 
classify patients treated predominantly with busulphan into 
three prognostic groups and Hasford et al performed a 
similar analysis in patients treated predominantly with IFN-
α. 
In the present study we evaluated our freshly diagnosed 
cases of CML for Sokal and Hasford score and graded them 
accordingly. According to Sokal score 5.1 % of our 59 
patients were placed in low risk group (score of < 0.8); 
44.0% in high risk group (score >1.2 %); and 50.8% in 
intermediate risk group (score 0.8 to 1.2). According to 
Hasford score 25 % were grouped under low risk group, 
44% in intermediate risk group and 30.5 % in high risk 
group. Thus Hasford score has placed 20% more patients in 
low risk group than Sokal score. The age range of these low 
risk patients is from 24 to 43 years. All Sokal low risk group 
patients were also Hasford low risk group patients, whereas 
the correspondence was much less for high risk patients. 
Thirteen of 26 patients of high Sokal were also high Hasford 
and the remaining 13 high Sokal cases were intermediate or 
even low with Hasford scoring system.  
In CML survival varies from few months to years from 
diagnosis and an accurate prediction of duration of survival 
could help patients and clinicians make decisions about 
many treatment options. We have analyzed prognostic 
stratification of patients using both Hasford and Sokal 
scores. The main difference between these scores is that 
Hasford score assesses the impact of eosinophils and 
basophils on differential white cell count at diagnosis. 
Although Sokal score is still widely used, studies suggest 
that it is no more the best method of reliability. In a study 
done by Thomas et al looking at survival of these groups 
(grouped both by Sokal and Hasford criteria) it was found 
that 5 years survival was better in their low risk groups.13 
They also suggested that Sokal was less informative as their 
survival curve of high risk group crossed the survival of low 
and intermediate risk groups several times. They 
recommended that Hasford is a better scoring system and is 
highly predictive of survival particularly in patients <60 
years age. In another study done by Hasford et al 9 (to 
validate Hasford scoring system) the Hasford scoring system 
was reinforced by finding that Sokal et al 14, 15 and 
Kantarjiar et al 8 do not separate the survival curves. In this 
study total number of their low risk group according to 
Hasford scoring system is 41.4% (with 5 year survival; 
75%) as compared to 25.5% in our study; intermediate 
group represented 44.5% (with 5 year survival of 56%) vs. 
44% in our study and 14.5% high risk group (with 5 year 
survival; 28%) vs. 30.5% in our study. Thus number of low 
risk group is quite low in our study and probably this is due 
to difference in selection criteria of patients as we have 
included patients in all phases and they included patients 
only in chronic phase. The results would have been different 
if we had followed the above mentioned criteria. In another 
study by Thomas et al11 (analyzing the patients using both 
Hasford and Sokal scoring systems) the number of their high 
risk group according to Hasford system was still lower (7% 
vs. 30.5% in our study), intermediate group (39% vs. 44% in 
our study) and the number of patients in their low risk group 
was quite high (55% vs. 25.5% in our study) 
The variables used in Hasford scoring system are routinely 
measured in clinical practice and their measurement is 
highly reliable. Thus one can get a reliable data needed for 
the calculation of this prognostic score. This scoring system 
has also shown a good discrimination of survival and can be 
considered a good tool for evaluation of risk adopted 
treatment. Allogeneic stem cell transplant is the only therapy 
that can cure CML, but age and lack of a suitable donor 
limit this procedure to a minority of patients.16   Sokal and 
Hasford Scores however do not predict survival after 
allogenic stem cell transplant.17 As for these patients 
pretransplant risk factors, i.e. donor type, stage of disease at 
time of transplantation, age of recipient, sex of donor and 
recipient, and interval between diagnosis and transplant are 
more important to predict their survival rate.18 Similarly 
with use of imatinib (particularly in previously untreated 
patients in chronic phase), different factors predict the 
duration of survival and overall survival is significantly 
better for patients treated initially with imatinib.19 
Journal of Islamabad Medical & Dental College (JIMDC); 1211(1):14-17 
 17 
Conclusion 
Hasford score identifies more patients still in low risk group 
as compared to Sokal scoring system Prospective studies to 
see overall survival and 5 year survival of patients in 
chronic phase particularly those less than 60 years who are 
unable to get imatinib and are on interferon therapy (after 
their prognostic categorization according to Hasford scoring 
system) will provide valuable information to 
oncologists/physicians both in stratifying patients into risk 
groups and modifying their treatment accordingly.    
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